WallStreetZenWallStreetZen

NASDAQ: RLMD
Relmada Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Be the first to know when Wall Street analysts revise their RLMD stock forecasts and price targets.

Forecast return on equity

Is RLMD forecast to generate an efficient return?

Company
-163.45%
Industry
274.69%
Market
231.01%
RLMD's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is RLMD forecast to generate an efficient return on assets?

Company
-123.45%
Industry
96.45%
RLMD is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

RLMD earnings per share forecast

What is RLMD's earnings per share in the next 3 years based on estimates from 3 analysts?

Avg 1 year Forecast
-$1.97
Avg 2 year Forecast
-$1.73
Avg 3 year Forecast
-$1.56

RLMD revenue forecast

What is RLMD's revenue in the next 3 years based on estimates from 3 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$0.0
Avg 3 year Forecast
$0.0

RLMD vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
RLMD$2.65N/AN/A
KPTI$5.16$15.40+198.45%Strong Buy
IMMX$3.15$8.00+153.97%Buy
ONCY$1.02$6.00+488.24%Strong Buy
KLRS$4.75$21.50+352.63%Strong Buy
View Top Biotech Stocks

Relmada Therapeutics Stock Forecast FAQ

What is RLMD's earnings growth forecast for 2025-2027?

(NASDAQ: RLMD) Relmada Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 48.09%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 42.93%.

Relmada Therapeutics's earnings in 2025 is -$67,809,013.On average, 3 Wall Street analysts forecast RLMD's earnings for 2025 to be -$65,341,027, with the lowest RLMD earnings forecast at -$62,778,634, and the highest RLMD earnings forecast at -$67,262,822. On average, 3 Wall Street analysts forecast RLMD's earnings for 2026 to be -$57,554,273, with the lowest RLMD earnings forecast at -$55,297,242, and the highest RLMD earnings forecast at -$59,247,045.

In 2027, RLMD is forecast to generate -$51,798,845 in earnings, with the lowest earnings forecast at -$49,767,518 and the highest earnings forecast at -$53,322,341.

If you're new to stock investing, here's how to buy Relmada Therapeutics stock.

What is RLMD's revenue growth forecast for 2025-2027?

(NASDAQ: RLMD) Relmada Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 108.99%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.77%.

Relmada Therapeutics's revenue in 2025 is $0.On average, 3 Wall Street analysts forecast RLMD's revenue for 2025 to be $0, with the lowest RLMD revenue forecast at $0, and the highest RLMD revenue forecast at $0. On average, 3 Wall Street analysts forecast RLMD's revenue for 2026 to be $0, with the lowest RLMD revenue forecast at $0, and the highest RLMD revenue forecast at $0.

In 2027, RLMD is forecast to generate $0 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $0.

What is RLMD's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: RLMD) forecast ROA is -123.45%, which is lower than the forecast US Biotechnology industry average of 96.45%.

What is RLMD's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: RLMD) Relmada Therapeutics's current Earnings Per Share (EPS) is -$2.22. On average, analysts forecast that RLMD's EPS will be -$1.97 for 2025, with the lowest EPS forecast at -$1.89, and the highest EPS forecast at -$2.03. On average, analysts forecast that RLMD's EPS will be -$1.73 for 2026, with the lowest EPS forecast at -$1.67, and the highest EPS forecast at -$1.79. In 2027, RLMD's EPS is forecast to hit -$1.56 (min: -$1.50, max: -$1.61).

What is RLMD's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: RLMD) forecast ROE is -163.45%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.